image credit: Pixabay

Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy

May 21, 2021

Data announced ahead of this year’s American Society of Clinical Oncology (ASCO) conference suggest that Gilead and CAR-T rivals Bristol-Myers Squibb and Novartis better watch their backs as Allogene announced plans for a pivotal study this year.

Allogeneic or “off the shelf” cancer cell therapies are derived from a bank of cells and can be manufactured and administered in bulk like drugs.

Meanwhile the autologous CAR-Ts already approved and on the market require patients’ T-cells to be harvested and genetically modified to fight cancer, an expensive and time-consuming process.

Read More on Pharmaphorum